BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

by · The Markets Daily

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price objective lifted by Cantor Fitzgerald from $27.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 203.66% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Wedbush reduced their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp raised their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

View Our Latest Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Trading Down 3.9%

BioCryst Pharmaceuticals stock opened at $9.55 on Tuesday. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -5.37 and a beta of 0.57. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $10.94. The stock’s 50 day moving average is $8.90 and its 200-day moving average is $8.27.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.20 earnings per share. As a group, equities research analysts predict that BioCryst Pharmaceuticals will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Phocas Financial Corp. acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $1,956,000. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after buying an additional 1,246,633 shares in the last quarter. Aberdeen Group plc acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $7,126,000. BNP Paribas Financial Markets lifted its position in shares of BioCryst Pharmaceuticals by 21.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after buying an additional 448,436 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of BioCryst Pharmaceuticals by 106.5% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock worth $1,820,000 after buying an additional 120,350 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

See Also